Immutep Limited (IMM.AX)
AUD 0.25
(2.08%)
AUD 0.25
(2.08%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 10.97 Million AUD | 35.68% |
| 2021 | 8.09 Million AUD | -7.61% |
| 2020 | 8.75 Million AUD | -34.13% |
| 2019 | 13.29 Million AUD | -17.68% |
| 2018 | 16.15 Million AUD | 19.86% |
| 2017 | 13.47 Million AUD | 59.84% |
| 2016 | 8.43 Million AUD | 16.51% |
| 2015 | 7.23 Million AUD | 14.98% |
| 2014 | 6.29 Million AUD | 125.93% |
| 2013 | 2.78 Million AUD | -21.88% |
| 2012 | 3.56 Million AUD | -19.95% |
| 2011 | 4.45 Million AUD | 75.28% |
| 2010 | 2.54 Million AUD | 14.29% |
| 2009 | 2.22 Million AUD | 228.41% |
| 2008 | 677.09 Thousand AUD | 260.51% |
| 2007 | 187.81 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 Q2 | 9.32 Million AUD | 0.0% |
| 2022 Q4 | 10.97 Million AUD | 0.0% |
| 2022 FY | 10.97 Million AUD | 35.68% |
| 2021 Q4 | 8.09 Million AUD | 0.0% |
| 2021 FY | 8.09 Million AUD | -7.61% |
| 2021 Q2 | 11.32 Million AUD | 0.0% |
| 2020 Q4 | 8.75 Million AUD | 0.0% |
| 2020 Q2 | 15.78 Million AUD | 0.0% |
| 2020 FY | 8.75 Million AUD | -34.13% |
| 2019 Q2 | 14.92 Million AUD | 0.0% |
| 2019 Q4 | 13.29 Million AUD | 0.0% |
| 2019 FY | 13.29 Million AUD | -17.68% |
| 2018 Q2 | 14.7 Million AUD | 0.0% |
| 2018 Q4 | 16.15 Million AUD | 0.0% |
| 2018 FY | 16.15 Million AUD | 19.86% |
| 2017 Q2 | 9.91 Million AUD | 0.0% |
| 2017 FY | 13.47 Million AUD | 59.84% |
| 2017 Q4 | 13.47 Million AUD | 0.0% |
| 2016 Q2 | 6.9 Million AUD | 0.0% |
| 2016 Q3 | 6.89 Million AUD | -0.11% |
| 2016 FY | 8.43 Million AUD | 16.51% |
| 2016 Q4 | 8.43 Million AUD | 22.24% |
| 2015 Q2 | 7.72 Million AUD | 0.0% |
| 2015 Q4 | 7.23 Million AUD | 0.0% |
| 2015 FY | 7.23 Million AUD | 14.98% |
| 2014 Q2 | 16.33 Million AUD | 0.0% |
| 2014 Q4 | 6.29 Million AUD | 0.0% |
| 2014 FY | 6.29 Million AUD | 125.93% |
| 2013 FY | 2.78 Million AUD | -21.88% |
| 2013 Q2 | 2.8 Million AUD | 0.0% |
| 2013 Q4 | 2.78 Million AUD | 0.0% |
| 2012 Q2 | 2.98 Million AUD | 0.0% |
| 2012 FY | 3.56 Million AUD | -19.95% |
| 2012 Q4 | 3.56 Million AUD | 0.0% |
| 2011 FY | 4.45 Million AUD | 75.28% |
| 2011 Q4 | 4.45 Million AUD | 0.0% |
| 2010 FY | 2.54 Million AUD | 14.29% |
| 2009 FY | 2.22 Million AUD | 228.41% |
| 2008 FY | 677.09 Thousand AUD | 260.51% |
| 2007 FY | 187.81 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | -209.935% |
| Biome Australia Limited | 5.37 Million AUD | -104.338% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 75.428% |
| Biotron Limited | 737.5 Thousand AUD | -1388.743% |
| Acrux Limited | 5.68 Million AUD | -93.065% |
| Alterity Therapeutics Limited | 5.42 Million AUD | -102.363% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -194.195% |
| BTC Health Limited | 203.94 Thousand AUD | -5283.53% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 14.243% |
| CSL Limited | 27.88 Billion AUD | 99.961% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | -31.78% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 60.944% |
| Memphasys Limited | 5.59 Million AUD | -96.331% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 74.325% |
| Noxopharm Limited | 1.28 Million AUD | -752.047% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -372.127% |
| Race Oncology Limited | 1.91 Million AUD | -472.921% |
| Starpharma Holdings Limited | 8.69 Million AUD | -26.231% |
| Tissue Repair Ltd | 1.35 Million AUD | -712.76% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -159.618% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -3478.177% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -2879.976% |
| Zelira Therapeutics Limited | 9.35 Million AUD | -17.346% |
| Patrys Limited | 691.36 Thousand AUD | -1488.105% |
| Orthocell Limited | 22.08 Million AUD | 50.279% |
| Imugene Limited | 33.14 Million AUD | 66.872% |
| PYC Therapeutics Limited | 10.18 Million AUD | -7.811% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -575.283% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -837.582% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -433.862% |
| Nanollose Limited | 465.64 Thousand AUD | -2257.944% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -2443.753% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -12714.212% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -220.404% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -950.053% |
| Nyrada Inc. | 855.63 Thousand AUD | -1183.214% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 95.597% |
| Dimerix Limited | 13.89 Million AUD | 20.97% |
| PharmAust Limited | 896.6 Thousand AUD | -1124.572% |
| Hexima Limited | 248.67 Thousand AUD | -4315.33% |
| AnteoTech Limited | 4.07 Million AUD | -169.421% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -206.321% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 30.917% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -1066.132% |
| Actinogen Medical Limited | 1.61 Million AUD | -579.697% |
| Immuron Limited | 2.84 Million AUD | -286.534% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -352.446% |